Case Page


Case Status:    ONGOING    
On or around 11/09/2018 (Ongoing date of last review)

Filing Date: November 08, 2018

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer.

On October 18, 2018, Endocyte issued a press release to announce the Proposed Merger between Endocyte and Novartis AG.

The Complaint alleges that on October 31, 2018, the Board authorized the filing of a materially incomplete and misleading preliminary proxy statement (the “Proxy”) with the Securities and Exchange Commission (“SEC”), in violation of Sections 14(a) and 20(a) of the Exchange Act.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: ECYT
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. New York
DOCKET #: 18-CV-10392
JUDGE: Hon. Jesse M. Furman
DATE FILED: 11/08/2018
CLASS PERIOD END: 11/08/2018
  1. Monteverde & Associates PC
    350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118
    (212) 971-1341 ·
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
No Document Title Filing Date